Horm Metab Res 2017; 49(05): 359-364
DOI: 10.1055/s-0043-102690
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Low Serum Sex Hormone-Binding Globulin Associated with Insulin Resistance in Men with Nonalcoholic Fatty Liver Disease

Juan Ye*
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
2   Guangxi Key Laboratory of Genomic and Personalized Medicine, Nanning, Guangxi, China
3   Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, Guangxi, China
4   Department of Epidemiology and Health Statistics, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
,
Ziting Yao*
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
2   Guangxi Key Laboratory of Genomic and Personalized Medicine, Nanning, Guangxi, China
3   Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, Guangxi, China
,
Aihua Tan
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
5   Department of Chemotherapy, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China
,
Yong Gao
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
,
Yingchun Chen
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
2   Guangxi Key Laboratory of Genomic and Personalized Medicine, Nanning, Guangxi, China
3   Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, Guangxi, China
,
Xinggu Lin
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
2   Guangxi Key Laboratory of Genomic and Personalized Medicine, Nanning, Guangxi, China
3   Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, Guangxi, China
,
Rongquan He
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
2   Guangxi Key Laboratory of Genomic and Personalized Medicine, Nanning, Guangxi, China
3   Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, Guangxi, China
,
Ruiqiang Tang
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
4   Department of Epidemiology and Health Statistics, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
,
Yanling Hu
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
6   Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, China
,
Haiying Zhang
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
7   Department of Occupational Health and Environmental Health, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
,
Xiaobo Yang
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
7   Department of Occupational Health and Environmental Health, School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
,
Qiuyan Wang
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
2   Guangxi Key Laboratory of Genomic and Personalized Medicine, Nanning, Guangxi, China
3   Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, Guangxi, China
,
Yonghua Jiang
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
2   Guangxi Key Laboratory of Genomic and Personalized Medicine, Nanning, Guangxi, China
3   Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, Guangxi, China
,
Zengnan Mo
1   Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China
2   Guangxi Key Laboratory of Genomic and Personalized Medicine, Nanning, Guangxi, China
3   Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, Guangxi, China
8   Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
› Author Affiliations
Further Information

Publication History

received 11 November 2016

accepted 24 January 2017

Publication Date:
10 March 2017 (online)

Preview

Abstract

The presence of nonalcoholic fatty liver disease (NAFLD) is a strong risk predictor for type 2 diabetes (T2D). A reduction in sex hormone-binding globulin (SHBG) is associated with NAFLD. Low SHBG is also associated with insulin resistance (IR). However, very limited data are available for the association of SHBG and IR in patients with NAFLD. The study aims to clarify the association between SHBG and IR in patients with NAFLD. In this cross-sectional study, 334 men with NAFLD were recruited. SHBG, total testosterone, free testosterone, total cholesterol, triglyceride, insulin, and glucose concentrations were measured. Homeostatic model assessment (HOMA)-IR and HOMA-β were calculated. Spearman’s correlations and multiple linear regressions were used to analyze the association between SHBG and IR. Men with moderate-severe NAFLD had higher waist circumference, BMI, total cholesterol, triglyceride, insulin, HOMA-IR, HOMA-β, and free testosterone, but lower SHBG than the mild NAFLD. The moderate-severe NAFLD group exhibited higher HOMA-IR (2.38±1.35 vs. 4.16±2.84, p<0.001) and lower SHBG (25.89±11.89 vs. 30.13±12.97 nmol/l, p<0.001) than the other group. SHBG value was negatively correlated with insulin, and HOMA-IR, but was not significantly correlated with glucose and testosterone. The multiple linear regression analysis showed that SHBG was significantly associated with insulin (β=− 0.241, p<0.001), and HOMA-IR (β=− 0.229, p<0.001), even adjusting for potential confounders. In conclusion, low serum SHBG is associated with IR in men with NAFLD.

* These authors contributed equally to this work